Clinical Trial Update: A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating padsevonil for drug-resistant focal-onset seizures was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-resistant Epilepsy
• Focal Onset Seizures

Drugs mentioned

• Padsevonil (padsevonil)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Drug-Resistant Epilepsy, Focal-Onset Seizures | Phase 3 | Status: TERMINATED | Results posted: 2021-10-25